Aspire Biopharma Holdings, Inc. (ASBP)
2025-06-30 | 2025-03-31 | |
|---|---|---|
| Sales and marketing | 51,311 | 219,839 |
| Research and development | 352,887 | 263,093 |
| General and administrative expenses | 395,692 | 15,073,548 |
| Total operating expenses | 799,890 | 15,556,480 |
| Interest expense | - | 289,931 |
| Interest expense | 527,893 | - |
| Loss on extinguishment of debt | -364,109 | - |
| Change in fair value of derivative liability | -289,401 | -94,917 |
| Total other (expense) income, net | -1,181,403 | -384,848 |
| Net loss | -1,981,293 | -15,941,328 |